Full Text
EE430 Evaluating the Cost Benefit of Fixed-Duration Targeted Therapy in First Line (1ST L) in Chronic Lymphocytic Leukemia (CLL ): A Real-World Analysis Using Hungarian Claims Data

Abstract

Authors

J Jeskó R Hegyi B Nagy

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×